{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:31:59Z","timestamp":1789684319670,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung Ho Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijbiomac.2026.151271","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:35:32Z","timestamp":1772696132000},"page":"151271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Engineering tumor-specific interferon-alpha-Nivolumab pro-immunocytokine for enhanced melanoma immunotherapy"],"prefix":"10.1016","volume":"354","author":[{"given":"Shi-Wei","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ting","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wen","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Tseng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Tse","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Jou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Ren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Han","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151271_bb0005","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.3390\/ijms25115794","article-title":"Melanoma management: exploring staging, prognosis, and treatment innovations","volume":"25","author":"Shalata","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151271_bb0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/ph17020214","article-title":"A review of current and pipeline drugs for treatment of melanoma","volume":"17","author":"Natarelli","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1029227","article-title":"Predicting melanoma survival and metastasis with interpretable histopathological features and machine learning models","volume":"9","author":"Couetil","year":"2023","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151271_bb0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without <i>BRAF<\/i> mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151271_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41571-018-0069-0","article-title":"Sequencing cells of the immune TME","volume":"15","author":"Killock","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151271_bb0030","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.955063","article-title":"Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures","volume":"13","author":"Hossain","year":"2022","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.151271_bb0040","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.3390\/cancers15143564","article-title":"Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients\u2019 responders to a first course of ICI: a multicenter national retrospective study of the French Group of Skin Cancers (Groupe de Canc\u00e9rologie Cutan\u00e9e, GCC)","volume":"15","author":"Nardin","year":"2023","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151271_bb0045","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms23052847","article-title":"Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment","volume":"23","author":"Dobosz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151271_bb0050","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151271_bb0055","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"issue":"450","key":"10.1016\/j.ijbiomac.2026.151271_bb0065","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.151271_bb0070","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151271_bb0075","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.179.4.2134","article-title":"Enhancement of human melanoma antigen expression by IFN-\u03b21","volume":"179","author":"Dunn","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2021.03.002","article-title":"Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10\/CXCR3 axis in hepatocellular carcinoma (HCC)","volume":"506","author":"Yan","year":"2021","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151271_bb0085","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.bbrc.2016.09.021","article-title":"STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation","volume":"478","author":"Takashima","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151271_bb0090","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7528","key":"10.1016\/j.ijbiomac.2026.151271_bb0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151271_bb0100","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.675873","article-title":"Prior therapy with pegylated-interferon alfa-2b improves the efficacy of adjuvant pembrolizumab in resectable advanced melanoma","volume":"11","author":"Jia","year":"2021","journal-title":"Front. Oncol."},{"issue":"35","key":"10.1016\/j.ijbiomac.2026.151271_bb0110","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.18.00632","article-title":"Phase Ib\/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma","volume":"36","author":"Davar","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151271_bb0115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40425-018-0428-5","article-title":"Neoadjuvant ipilimumab (3 mg\/kg or 10 mg\/kg) and high dose IFN-\u03b12b in locally\/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire","volume":"6","author":"Tarhini","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1249330","article-title":"Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy","volume":"14","author":"Razaghi","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151271_bb0125","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1038\/s41467-023-40028-z","article-title":"A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors","volume":"14","author":"Zibelman","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151271_bb0130","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151271_bb0135","doi-asserted-by":"crossref","first-page":"11587","DOI":"10.1038\/s41598-017-11886-7","article-title":"Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.130945","article-title":"Selective activation of IFN\u03b3\u2013ipilimumab enhances the therapeutic effect and safety of ipilimumab","volume":"265","author":"Huang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00856","article-title":"MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAFV600E mutation detected in circulating-free DNA","volume":"9","author":"Salemi","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151271_bb0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-020-00652-z","article-title":"Ab locks for improving the selectivity and safety of antibody drugs","volume":"27","author":"Lin","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0155","series-title":"Progress in Molecular Biology and Translational Science","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/bs.pmbts.2017.04.003","article-title":"Chapter ten - matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders","author":"Liu","year":"2017"},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606489","article-title":"The role of structure in the biology of interferon signaling","volume":"11","author":"Walter","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656908","article-title":"The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment","volume":"12","author":"Laha","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.151271_bb0170","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41416-022-01743-4","article-title":"Biomarkers of response to PD-1 pathway blockade","volume":"126","author":"Li","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151271_bb0175","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151271_bb0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.151271_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228302","article-title":"PD-L1 upregulation by IFN-\u03b1\/\u03b3-mediated Stat1 suppresses anti-HBV T cell response","volume":"15","author":"Liu","year":"2020","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151271_bb0190","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151271_bb0195","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151271_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219829","article-title":"Empowering therapeutic antibodies with IFN-\u03b1 for cancer immunotherapy","volume":"14","author":"Guo","year":"2019","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151271_bb0205","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.151271_bb0210","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.151271_bb0215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ctrv.2018.08.001","article-title":"Patient-reported outcomes with nivolumab in advanced solid cancers","volume":"70","author":"Tykodi","year":"2018","journal-title":"Cancer Treat. Rev."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026011979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026011979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:39:29Z","timestamp":1777484369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026011979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"alternative-id":["S0141813026011979"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151271","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering tumor-specific interferon-alpha-Nivolumab pro-immunocytokine for enhanced melanoma immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"151271"}}